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Although faecal and endoscopic tests appear to be eﬀective in reducing colorectal cancer incidence and mortality, further
technological and organizational advances are expected to improve the performance and acceptability of these tests. Several
attempts to improve endoscopic technology have been made in order to improve the detection rate of neoplasia, especially in the
proximal colon. Based on the latest evidence on the long-term eﬃcacy of screening tests, new strategies including endoscopic and
faecal modalities have also been proposed in order to improve participation and the diagnostic yield of programmatic screening.
Overall, several factors in terms of both eﬃcacy and costs of screening strategies, including the high cost of biological therapy for
advanced colorectal cancer, are likely to aﬀect the cost-eﬀectiveness of CRC screening in the future.
1.Introduction
Colorectal cancer (CRC) can be prevented as more than 85%
of tumors arise in a premalignant polyp. Therefore, the aim
of CRC screening is to reduce mortality and, if possible,
the incidence of the disease by identifying individuals with
presymptomatic neoplastic lesions who may require further
examination and treatment [1].
The most extended CRC screening strategies are based
either on annual or biennial fecal occult blood tests, with
colonoscopy reserved for patients testing positive, or on
endoscopic procedures performed one-time or every 5 years
for ﬂexible sigmoidoscopy (FS) or every 10 years in the
case of colonoscopy. In addition, other screening procedures,
such as CT colonography and fecal DNA analysis, are under
current investigation.
Compliance to screening and accuracy of the screening
tests are the two major determinants of the eﬀectiveness of a
screening program. Although evidence from several studies
have shown that some of the above-mentioned strategies
are eﬀective [1–4] and cost-eﬀective [5], participation is still
poor with compliance rates lower than 50% in population-
based programs carried out in Europe and USA. This is
a current bone of contention since it has been suggested
that new strategies, including either the combination of
established tests (i.e., fecal immunochemical test (FIT) and
endoscopic procedures) or the implementation of novel
screening tests that do not require bowel preparation and do
notcausediscomfort(i.e.,bloodbiomarkers)mightsubstan-
tially improve the current adherence to CRC screening.
During the last decade there has been a marked im-
provement in the performance of the screening tests for
detectingCRCandpreneoplasticlesions.Severalrandomized
controlled trials have shown that the novel semiquantitative
fecal immunochemical tests (FITs) are better accepted [6]
and have a better performance than the traditional chemical
(guaiac) test for detecting colorectal neoplasia [7, 8]. In
addition, new technologies (i.e., image-enhanced endoscopy
(IEE)) have been introduced to improve endoscopic polyp
detection [9], although its inﬂuence in the framework of
screening still needs to be deﬁned.
CRC screening is not only an eﬀective tool for reducing
CRC-related mortality and incidence, but also has been
estimated to do so at acceptable costs. Almost ten years ago,
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that costs per life-year gained of the diﬀerent screening
strategies ranged between 10.000$ and 25.000$. However,
several of the screening methods considered today as ﬁrst-
choicescreeningstrategies(i.e.,FIT)werenotavailableatthe
time of the USPSTF report. Recent evidence has conﬁrmed
that CRC screening continuous to be cost eﬀective compared
to no screening, irrespective of the screening test used.
However, cost-eﬀective analysis does not clarify what is the
optimal test for CRC screening, because of the uncertainty
surrounding many aspects of such interventions.
In this paper, we discuss the possible contribution of the
new endoscopic technologies, as a useful tool for screening
colonoscopy. In addition, we put in perspective the current
strategies for CRC population-based screening and discuss
the convenience for combining the established strategies in
thenearfuture.Finally,weaddressthefactorsthatdetermine
cost-eﬀective analysis in the setting of CRC screening.
2.Impact ofNew Endoscopic Technologies in
CRC Prevention
Colonoscopy is considered the gold standard for the detec-
tion of neoplastic lesions at risk of progression to CRC
and is recommended as a ﬁrst-line screening test in aver-
age and high-risk populations. Its main advantage is that
removal of adenomas or early cancer can be performed
during the same procedure whereas all other screening
tests require colonoscopy for conﬁrmation and removal.
However, colonoscopy has also important limitations: ﬁrst,
the risk of major complications (postpolypectomy bleeding
and perforation [10] are estimated very low (0.1 and 0.3%,
resp.)) for symptomatic patients, but still may be relevant in
the framework of screening programs, where asymptomatic
subjects are explored; second, although colonoscopy is
consideredthereferencestandardforthedetectionofcolonic
neoplasia, polyps are still missed. A substantial adenoma
miss rate of 20 to 26% for any adenoma and of 2.1% for large
adenomas (≥10mm) was reported in tandem colonoscopy
studies [11]. Adenoma detection rate is highly dependent on
quality standards including colonoscopist skills, technology,
and several patient-related factors [12]. This section reviews
the new endoscopic technologies that may signiﬁcantly
reduce the adenoma miss detection rate associated with
conventional colonoscopy.
2.1. Wide-Angle Colonoscopy. A prototype wide-angle col-
onoscope did not eliminate polyp miss rates [13], however,
simulation of a colonoscope with a 170-degree ﬁeld of view
resulted in 6% reduction compared with the commonly
available140-degreeangleofviewofmostcolonoscopes.The
latest generation of wide-angle high-deﬁnition colonoscopes
improvesratesofadenomadetectionby22%,comparedwith
older technology endoscopes used in routine private practice
[14].
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roscope (TER) (Avantis Medical Systems, Inc, Sunnyvale,
CA, USA) is a newly developed imaging device providing
a retrograde image of the colon. This device has proved
eﬀective in improving polyp detection on the proximal sides
of folds in animal models [15] and has also proved safe
in humans [16, 17]. Contrarily to wide-angle colonoscopy,
TER has the inconvenience of requiring the visualization of
dual monitors by one endoscopist and the occupation of the
scope’s biopsy channel, making diﬃcult its use in routine
clinical practice.
2.3. Image-Enhanced Endoscopy (IEE). New image-enhanced
endoscopy (IEE) such as narrow band imaging (NBI) system
and endoscopic autoﬂuorescence imaging (AFI) system have
been developed in order to visualize ﬂat-type colorectal
tumorortumor’ssurfacemucosalorcapillarypatternclearly.
2.3.1. Narrow Band Imaging (NBI) System. NBI has been
shown to be helpful for early detection of superﬁcial cancer
in the head and neck region and the esophagus [18]. In
the colorectal region, this modality was expected to enable
early detection of adenoma lesions; however, both positive
[19, 20] and negative [21–24] results have been reported,
andsomeresearchershaveconcludednoimprovementinthe
adenoma detection rate of NBI compared with white-light
colonoscopy (WLC).
One reason for these conﬂicting ﬁndings could be
the diﬀerence between the optical-electronic technologies
employed in videoendoscopes in the NBI systems used
sequential system (LUCERA; Olympus Optical Co.) versus
nonsequential system (EXERA II; Olympus Optical Co.).
Further, diﬀerences in the endoscope (low resolution versus
high resolution) and imaging (surface structure enhance-
ment and index of hemoglobin color enhancement) settings
can inﬂuence the detection of the same lesion. Moreover, the
colonoscopist’s experience may have a considerable impact
on the detection rate: if the colonoscopist does not have
suﬃcient training in chromoendoscopy of ﬂat and depressed
lesions with an NBI system, the usefulness of NBI for
adenoma detection may not be evident. Finally, most of the
previous studies used a single-center design.
We reported that the A-5 image setting of the surface
structure enhancement function together with the level 3
adaptive index of hemoglobin color enhancement function
seem to be the most suitable for detection of colorec-
t a la d e n o m a s[ 25, 26]. To overcome the aforementioned
confounding factors, we evaluated the colonic adenoma
detection rate of NBI versus WLC by using consistent NBI
system, endoscope, and imaging settings in a multicenter
randomized trial (RCT) using cross-over design. This RCT
was conducted in the right colon for 813 patients using
high-deﬁnition colonoscopy and NBI settings with surface
structure enhancement. This large randomized trial did not
show any objective advantage of NBI over WLC in terms of
improved neoplastic lesion detection.
2.3.2. Autoﬂuorescence Imaging (AFI) System. AFI produces
real-time pseudocolor images to identify gastrointestinal
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cervix, lung, and bladder. During AFI colonoscopy, non-
neoplastic lesion appears green, while neoplastic lesion
has a magenta (reddish purple) image. The usefulness
of AFI for diﬀerential diagnosis between neoplastic and
nonneoplastic lesions has been reported; however, there is
scarce information regarding its eﬀectiveness for colorectal
polypdetectionincomparisonwithconventionalwhite-light
colonoscopy (WLC). Therefore, the utility of AFI to improve
colorectal tumor detection still remains controversial. We
therefore conducted a pilot study to evaluate whether AFI
can detect more colorectal polyps than WLC. Interestingly,
our study showed that AFI system improved the detection of
right-sided colonic polyps, especially ﬂat and/or diminutive
adenomatous lesions compared to conventional WLC.
In the future, further trials should be performed to
validate the usefulness by the combined use of AFI and NBI
system for CRC screening.
2.4. Capsule Endoscopy. Colon capsule endoscopy is a new
technique to visualize the colon, originating from small
bowel imaging. Van Gossum et al. [29] were the ﬁrst
to evaluate the eﬀectiveness in a prospective setting. In
high-risk patients, sensitivity and speciﬁcity for detecting
polyps ≥6mm were 64 and 84%, respectively, whereas
sensitivity and speciﬁcity for advanced adenoma detection
were 73% and 79%, respectively. The accuracy of the second-
generationcoloncapsuleforadenomadetectionwaspromis-
ing, with an estimated higher sensitivity and speciﬁcity [30].
Compared with full colonoscopy, the accuracy of colon
capsule is considerably lower and an even more extensive
bowel cleansing is needed. Capsule endoscopy has not yet
been evaluated in an average risk screening population.
In summary, total colonoscopy is accepted as the most
accurate method of investigation for the large bowel,
however, colonoscopy still may miss lesions responsible
for cancer development. Several novel devices have been
introduced to ﬁnd ﬂat or depressed tumors or lesions hidden
behind folds in the colon. Although some of these emer-
gent technologies such as wide-angle colonoscopy markedly
reduce the rate of missed polyps other more sophisticated
devices (TER, NBI, and AFI) needs further evaluation.
3. New Strategies for Population-Based
CRC Screening
3.1. Technology Innovation for Established Strategies. The
adoption of guaiac-fecal occult blood test (g-FOBT) for
CRC screening is supported by sound experimental evidence
from the US and European trials, which demonstrated
that regular screening is associated with a reduction in
CRC speciﬁc mortality and, in the context of the US
study using rehydrated g-FOBT, also with a reduction in
CRC incidence. Although this method, adopted by several
nation-wide programs in Europe (Finland, UK, and France)
can be suitable for population screening, it carries several
limitations. Indeed, the test processing and analysis are not
automated and therefore they are labor intensive and involve
subjective visual reading, while it is not possible to adjust its
cutoﬀ for Hb concentration. Also g-FOBT is not speciﬁc for
human Hb and it showed a low sensitivity for CRC and even
more so for advanced adenomas.
Technology developments have been subsequently intro-
duced to overcome some of these limitations. A signiﬁcant
enhancement has been achieved by using antibodies speciﬁc
t oh u m a ng l o b i nt od e t e c th u m a nb l o o dp r e s e n ti nf e c e s .A s
with g-FOBT, the presence of blood in a fecal sample can be
used as a marker to detect signiﬁcant neoplasia in otherwise
asymptomatic people. The potential advantages of these
alternative fecal tests based on immunochemical technology
(FIT) include the possibility of an automated processing and
analysis, allowing for the possibility to adjust the cut oﬀ
of Hb concentration, and the increase in the test speciﬁcity
for human Hb. The immunochemical technique increases as
well the test sensitivity, as it allows to detect smaller blood
losses. The disadvantages of FIT methods include sample
instability, which impose speciﬁc organizational constraints,
and the cost of the test. Cost is however highly dependent on
local and national market conditions, while the automated
testing process with high throughput devices can oﬀset the
higher cost of the kit.
Two recent large trials conducted among average risk
people showed a higher attendance and detection rate of
advanced adenomas and CRC of FIT compared to g-FOBT
screening [6, 8]. These trials conﬁrmed the ﬁndings of
previous comparative studies suggesting the superiority of
FIT over g-FOBT [7, 31–35]. Based on this evidence, FIT was
recently recommended as the test of choice for population
screening in the European Guidelines on quality assurance
for CRC screening [36]. The availability of an increasing
variety of FIT devices on the market will likely require the
adoption of standard and explicit criteria for assessing those
device characteristics, including ease of use, sample stability
and transport requirements, reproducibility of test results,
cost of the kit and of processing, which need to be taken into
accountwhenselectingthemostappropriatekitforaspeciﬁc
program.
3.2. Endoscopic Screening: New Evidence and Open Issues.
Most countries implementing population-based CRC
screening programs have adopted g-FOBT and, more
recently, FIT. Only a few pilot projects and two population-
based programs in Italy adopted FS as a screening option,
while colonoscopy was proposed as primary test for
opportunistic screening in the USA, Germany, and Poland.
New evidence accumulating over the past few years lead to
a change of this scenario, both in terms of evidence and of
available strategies.
3.2.1. Sigmoidoscopy. Evidence for endoscopic screening was
based, until last year, on observational studies, showing
a reduction of the risk of CRC or of CRC-related death
amongpeopleundergoingendoscopy,orontrialscomparing
sigmoidoscopy with g-FOBT or FIT, showing a substantially
higher yield of neoplasia of a single FS examination as
compared to a single round of g-FOBT or FIT screening.
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long-term follow-up results [2, 37] consistently indicated
that the endoscopic excision of colorectal adenomas is
associated with a reduction of CRC incidence and mortality.
The estimated incidence reduction in the intention to treat
analysisis23%at12yearsintheUKtrialand18%at11years
in the SCORE trial; the reduction is higher among people
undergoing screening, as shown in the perprotocol analysis,
with a 33% and 31% CRC incidence reduction, respectively.
Contrary to previous reports [38] suggesting that FS might
not be eﬀective among women, the protective eﬀect of FS
screening is the same for men as for women in the two trials.
The substantial and long-lasting reduction of CRC
incidence, which is still about 80% lower than expected at 10
years in the distal colon, supports the hypothesis of a plateau
of the prevalence of distal adenomas [39].
The adoption of a screening strategy based on the oﬀer
of the test once in the lifetime seems therefore justiﬁed,
although the optimal target age range has not been deﬁned
yet. In Italy, FS screening is currently oﬀered to subjects
aged 58 or 60 [40], targeting a new birth cohort every year,
while the UK pilot will target people in the age range 55
to 59. However, no diﬀerence in the protective eﬀect of FS
screeningcouldbeobservedintheUKandItaliantrialswhen
comparing people younger than 60 to those aged 60 to 64.
As long as it might be ineﬃcient, or not feasible, to target all
peopleaged55to64,theissueofdeﬁning aspeciﬁcagerange
for screening is relevant to the planning of population based
interventions. Pooled analyses of the published, as well of the
ongoing trials, might be useful to determine if a narrower
age range, than the two age classes considered in the main
analyses, can be identiﬁed.
The reduction of proximal CRC incidence and mortality
was low and nonsigniﬁcant, ranging between 3% in the
UK trial and 15% in the SCORE trial among those who
were screened. The observed diﬀerence might be related to
the higher referral rate for total colonoscopy in the Italian
trial, although the estimated additional yield of proximal
advanced neoplasia associated with the strategy adopted in
the SCORE trial was negligible. The results of the ongoing
trials adopting diﬀerent referral criteria might oﬀer useful
information to assess the impact of less restrictive total
colonoscopy referral policies on the risk of proximal CRC.
Thepositiveimpactofhighreferralratesmightbelowerthan
expected, however, as evidence mounts that colonoscopy
may not prevent as many cancers in the right colon as in the
left.
3.2.2. Colonoscopy. Several observational studies [41–43]
demonstrated the overall eﬀectiveness of colonoscopy for
reductionofCRCincidenceandmortality,butwithamarked
variance in eﬀectiveness for proximal and distal cancer.
A substantial protective eﬀect could be observed for CRC
arising in the distal colon, while no eﬀect was observed
in the proximal colon. Only one recent case-control study
[43] indicated that colonoscopy might represent an eﬀective
tool to prevent proximal CRC, although an eﬀect could be
observed only among people older than 60. This ﬁnding
is consistent with the results of the Italian SCORE3 trial
[44] comparing FS and colonoscopy, which showed that the
detection rate was higher for total colonoscopy screening
comparedwithFSscreening onlyforpeople aged60orolder.
It might be related to the known shift to the right of
CRCs with age, but the underlying reasons for the observed
diﬀerence in colonoscopy performance in the proximal and
distal colon are still unclear. Uncertainties are related to the
role of biological diﬀerences that may limit the potential
eﬀectiveness of colonoscopy in the proximal colon. The
relative frequency of nonpolypoid lesions, which are harder
to identify and remove, tends to be higher in the right
colonic segments. The predominant genetic pathways of
carcinogenesis may diﬀer between left-sided and right-sided
cancers, with a higher frequency of serrated neoplasms in the
proximal colon. Also, contrary to the trend observed in the
distal colon, no evidence of a plateau for the incidence of
proximal adenomas has been reported.
The assessment of the protective eﬀect for proximal
CRCs achievable with colonoscopy represents therefore the
most relevant outcome of RCTs evaluating eﬀectiveness
of colonoscopy screening. Comparative studies should be
designed to assess whether the magnitude of the incremental
beneﬁt of colonoscopy over FS is suﬃcient to justify the
additional risks and costs of colonoscopy for screening in
thepopulation.Thesestudiesshouldalsoshedlightonissues
concerningtheactualimplementationofascreeningstrategy
based on colonoscopy, such as the deﬁnition of a target age
range as well as, eventually, of a screening interval.
3.3. Combined Strategies. Given the limitations of available
endoscopy methods, strategies combining FS with FIT
representanoptionwhichdeservesconsideration,asitmight
ensure an additional beneﬁt over FS alone, in particular for
proximal lesions. The potential value of this approach, as a
recommended option for CRC screening, is supported by
a decision analysis using microsimulation models, included
in the latest version of the USPSTF, which showed that a
strategy using FS and FIT can have an impact, in terms of life
years saved, comparable with that of colonoscopy, assuming
a comparable participation to the screening process. Data
concerning the actual impact of such strategy are only
available from colonoscopy studies estimating the relative
contribution of FOBT or FIT and of a surrogate FS. Prospec-
tive studies aimed at assessing the performance of such
strategy in the context of screening interventions targeting
averageriskpeoplearelacking.Theresearchquestionofsuch
studies should be focused on identifying the best way to add
FIT to a FS screening program to achieve an increased yield
of proximal neoplasms while ensuring high participation
rates.
3.4. Promoting Participation while Ensuring High Quality of
theScreeningProcess. TheUSPSTFCRCscreeningguidelines
pointed out that for all screening modalities the eﬀectiveness
of screening decreases substantially as adherence to the regi-
men declines. They further stated that at the individual level
adherence to a screening regimen will be more important
in life years gained than the particular screening regimen
selected.Gastroenterology Research and Practice 5
Availability of diﬀerent tests represents indeed a new sce-
nario for mass screening programs, as subject’s preferences
and attitudes will likely inﬂuence the uptake level achievable
withdiﬀerent strategies.There is agrowing body ofliterature
suggesting that subjects targeted for CRC screening have
clear preferences for speciﬁc methods, determined by test
characteristics. Also, gender, education, and age are associ-
ated with the uptake, according to the reports from several
studies showing higher response rate among women invited
to undergo FIT [6] and a higher attendance rates to FS
screening among men and more educated or younger people
[6].
The heterogeneity of patient’s preferences for how to be
screened would therefore support the adoption of strategies
favoring their implementation as a possible mean to improve
participation in CRC screening, but available evidence for
this approach is still limited.
Finally, for screening programs to obtain the optimum
result, a high quality of the screening process is needed.
Poor quality of the exam has been proposed as one of
the possible factors explaining the lack of a protective
eﬀect of colonoscopy for proximal CRC. Indeed, inadequate
performance of colonoscopy may limit its eﬀectiveness, in
particular in the proximal colon, as suggested also by the
ﬁnding of a higher proportion of interval CRC in the right
colon compared to the distal colon. Eﬀorts to improve
quality are therefore needed, taking into account that
colonoscopy represents not only a potential tool for primary
screening, but it is also recommended as a diagnostic tool for
people with positive results from diﬀerent primary screening
tests. These same eﬀorts should however be implemented
also for all the recommended screening methods. A wide
variability in adenoma detection rate has been observed in
the context of the trials and programs adopting FS [45–48]
and also in the context of FOBT/FIT-based screening quality
of laboratory procedures deserves adequate scrutiny.
4. Cost Effectiveness of CRC Screeningin
the 21st Century
The main purpose of cost-eﬀective models is to provide rea-
sonable estimates on the expected eﬃcacy and convenience
of health interventions to the policy makers and, more in
general, to the whole society. This in turn may be expected to
drive selective implementation of new policies to reduce the
burdenofanydiseaseintermsofmorbidity/mortalityand/or
treatment-related costs. A further advantage of cost-eﬀective
models is to allow a transparent comparison of eﬃcacy and
eﬀectiveness among diﬀerent specialties, in order to allow a
productive distribution of economic and ﬁnancial resources
among the diﬀerent ﬁelds. For this reason, the main results
of cost-eﬀective models may be expected to be incorporated
in clinically orientated guidelines, impacting eventually the
clinical ﬁeld.
Cost eﬀectiveness is critical when applied to health
interventions directed to the general population, because
of the relevance of both eﬃcacy and cost outcomes. This
occurs with breast, cervical, as well as with CRC screening,
in which all the population included within a predetermined
age cutoﬀ is expected to be invited for the screening
intervention. Because of the ethical implications implied in
invitingasymptomaticsubjects,policymakersmaybewilling
to be reassured about the potential eﬃcacy of a population
intervention in terms of risk/beneﬁt ratio. Secondly, because
of the large number of people to be screened, generally
several millions in each country, policy makers need to be
aware of the magnitude of absolute costs to be invested and
on the convenience of the intervention.
The main drawbacks of cost-eﬀective models is that,
despite the apparent ﬁrmness of the cost-eﬀectiveness ratios,
cost-eﬀective estimates resound of the underlying uncer-
tainty on the main assumptions postulated when developing
the simulation process. Such uncertainty may aﬀect the
conﬁdence on any cost-eﬀective outputs, reducing its role
in the policy-making process. For this reason, simulation
models will never replace clinical estimates on the eﬃcacy
of health interventions, such as randomized or controlled
clinical studies, which, on the other hand, are absolutely
necessary to reduce the degree of uncertainty surrounding
cost-eﬀective estimates.
When dealing with CRC screening, cost-eﬀective anal-
ysis has consistently shown the favorable proﬁle of CRC
screening, irrespectively of the adopted strategy. Such favor-
able cost-eﬀectiveness, as compared with other medical
interventions (i.e., breast cancer screening or renal hemo-
dialysis), appeared to be strictly related with the possibility
to prevent not only CRC mortality, but also CRC incidence.
Any reduction of CRC incidence will not only nullify the
CRC-related mortality, but it will also lead to substantial
saving, because of the exclusion of surgery/chemotherapy
costs. However, cost-eﬀective simulations did not reach
clear conclusions on the optimal test for CRC screening,
because of the uncertainty surrounding several aspects
of such interventions. Despite less relevant, there is also
persistent uncertainty on the optimal age window for CRC
screening, as well as on the intervals after negative screening
tests or following polypectomy. For this reason, further
evolutions in this ﬁeld may arise from the acquisition of new
information on both the eﬃcacy and costs of the diﬀerent
tests recommended for CRC prevention.
4.1. Eﬃcacy. Several sources of uncertainty on the relative
eﬃcacy of diﬀerent CRC screening tests exist in simulation
models. First, the natural history of the adenoma-carcinoma
sequence has only partially been clariﬁed. For instance,
the progression from low- to high-risk polyps, as well as
amongdiﬀerentsizeclasses(i.e., ≤5,6–9, ≥10mm),ispoorly
known. Similarly, the information on the progression from
large polyps to CRC only relies on one old radiological
study at high risk of selective/interpretative bias. The nat-
ural history of CRC is also incompletely clariﬁed. Despite
the stage-speciﬁc survival rates are well documented, the
sojourntimesamongthediﬀerentstagesbeforethediagnosis
have only indirectly been estimated. Finally, the relative
rate between CRC arising along the adenoma-carcinoma
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of this uncertainty, models tend to diﬀer on the estimates
on the transition rates among the several steps of the CRC
cancerogenesis, eventually leading to uncertainty on the
superiority of one test over the other. It is self-evident that
models in which the adenoma-carcinoma sequence is simu-
lated to be relatively low will favour infrequent, but highly
sensitive tests for polyps, such as endoscopy or radiology,
whilst models simulating a more accelerated carcinogenesis
will favour more frequent CRC-sensitive tests, such as
fecal tests. Secondly, there is uncertainty on the long-term
eﬃcacy of several screening tests. Such uncertainty mainly
depends on the lack of appropriate trials addressing such
issue. For instance, there is uncertainty on the long-term
eﬃcacies of immunochemical fecal test in preventing both
CRC mortality and incidence. Similarly, there is uncertainty
on the additional eﬃcacy when repeating such tests more
frequently (annual versus biannual). Despite widely used as
opportunistic screening test, colonoscopy, diﬀerently from
sigmoidoscopy, has never been fully validated in randomized
trials. Moreover, there are wide discrepancies on the exact
rate of CRC prevention with this technique, ranging from
30% to virtually 100%. Thirdly, there is uncertainty on how
selective strategies of prepolypectomy ﬁltering may aﬀect
the eventual eﬃcacy of noninvasive strategies. For instance,
it is unclear whether the selective exclusion of ≤5mm or
≤10mmpolypswithCTcolonographyorcapsuleendoscopy
will sort out in a reduced protection as compared with the
endoscopic techniques in which all the polyps are usually
removed. Fourthly, when basing simulations on diagnostic
rather than population estimates, there is uncertainty on the
reproducibility and generalizability of the data. For instance,
diﬀerent immunochemical fecal tests have shown a wide
interval of sensitivity values, and, similarly both endoscopic
and radiological tests have shown diﬀerent estimates of
accuracy in relation to the study setting.
It is clear that only the progressive acquisition of new
and more complete information on all these diﬀerent aspects
related with the eﬃcacy of the tests will allow simulation
models to produce a more realistic and valuable comparison
amongthediﬀerenttests.Forinstance,therecentpublication
of two high-quality trials on sigmoidoscopy substantially
reduced the uncertainty on the eﬃcacy of this test on both
CRC incidence and mortality, improving the reliability of its
modelling. The same will probably applied to colonoscopy,
when the ﬁnal results of the ongoing trials will become
available.
4.2. Costs. The main determinants of costs in CRC screening
modelling are represented by the procedural costs and the
costs related with CRC treatment. Procedural costs will in
turn depend on the cost estimate and on the actual exploita-
tion of the diﬀerent procedures. Despite it is relatively simple
to obtain realistic estimates of procedural costs under the
Medicare scenario, there is a high degree of variability and
lack of transparency among the several US insurances used
by <65 year old Americans. Similarly, the reimbursement
cost for medical procedures in the public health systems
in Europe tends to substantially underestimate the actual
exploitation of medical and economic resources, artiﬁcially
improving the cost-eﬀectiveness proﬁle of CRC screening
test.Testspeciﬁcityisalsoamajordeterminantofprocedural
cost. Consequently, the uncertainty on the exact speciﬁcity
of fecal tests for advanced adenomas or of radiological
procedures for the selected polyp cutoﬀ will generate a huge
variability on the ﬁnal cost-eﬀective estimates. A further
cause of uncertainty is related with the application of a
ﬁnancial discounting on the costs occurring in the future
years, based on the psychological consideration that money
to be spent in the present are considered more valuable
as compared to money to be spent in the future. Despite
understandable, such assumption will tend to underestimate
the absolute burden of costs, potentially advantaging more
expensive screening strategies, such as endoscopy or radiol-
ogy. Thirdly, cost-eﬀectiveness ratio tend to mix between the
investmentsneededinthestart-upphasewiththoserequired
in the following workup of the screening program. However,
policy makers tend to provide a higher value to the start-
up phase, since the required investments will mainly incur
in their running period. This may be one of the reasons for
which fecal test-screening program are still favoured in most
of the European countries.
In conclusion, we may expect a high degree of evolution
from cost-eﬀective models. Such evolution should achieve
the diﬃcult task to match the progressive acquisition of
clinical information with the actual need and availability
of the society. The ultimate aim will be to provide a clear
ranking of eﬃcacy and costs of the diﬀerent choices with a
minimal degree of uncertainty on the correctness of these
estimates.
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